 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...2627282930313233343536...7475» |
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-World Evidence: Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study. (Pubmed Central) - Mar 6, 2021
There were no new safety signals. These results may help inform routine clinical practice to appropriately treat nAMD patients with ranibizumab to achieve optimal visual outcomes.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Intravitreal ranibizumab for the management of serous maculopathy secondary to optic disc coloboma-associated choroidal neovascularisation. (Pubmed Central) - Mar 2, 2021
This report contributes to the evidence that maculopathies associated with cavitary optic nerve anomalies may in some instances result from choroidal neovascularisation. It also highlights the importance of angiography to identify potential choroidal neovascular membranes, particularly in the absence of haemorrhages and neovascular membranes on fundus examination and conventional optical coherence tomography.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Antiangiogenic therapy of neovascular age-related macular degeneration (Pubmed Central) - Feb 28, 2021
Even though the topic of nAMD therapy is widely highlighted in modern ophthalmology, today there are many aspects that require targeted solutions. The main controversial issues that determine the complexity of therapy and patient management include discrepancies in determination of reference points (disease activity criteria) for implementation of anti-VEGF dosing regimens, patients' compliance, prioritization issues in treatment, its continuity with potential for the increase of intervals between injections and monitoring visits.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity. (Pubmed Central) - Feb 27, 2021
The main controversial issues that determine the complexity of therapy and patient management include discrepancies in determination of reference points (disease activity criteria) for implementation of anti-VEGF dosing regimens, patients' compliance, prioritization issues in treatment, its continuity with potential for the increase of intervals between injections and monitoring visits. The IVR might contribute to microvascular changes in the macular zone, such as reducing the central foveal VLD and PD, while the LP might contribute to microstructural changes, such as smaller FAZ and thicker CFT.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, Real-World Evidence: ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD). (Pubmed Central) - Feb 27, 2021
P=N/A
Although broad agreement on CNV activity parameters was observed between clinicians and RCs, correct identification of CNV activity did not always lead to the initiation of (re-)treatment. To preserve vision over time, correct interpretation of SD-OCT scans and careful retreatment decisions are required.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Reimbursement, Journal, HEOR: Intravitreal Anti-Vascular Endothelial Growth Factor Cost Savings Achievable with Increased Bevacizumab Reimbursement and Utilization. (Pubmed Central) - Feb 27, 2021
To preserve vision over time, correct interpretation of SD-OCT scans and careful retreatment decisions are required. Increased utilization of bevacizumab achievable with increased reimbursement to eliminate the financial disincentive to its use would result in substantial savings to the Medicare Part B program and to patients receiving anti-VEGF intravitreal injections.
- || Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Ranibizumab: A Review in Retinopathy of Prematurity. (Pubmed Central) - Feb 27, 2021
Overall, ranibizumab is an effective and generally well tolerated treatment for ROP and is not associated with systemic VEGF suppression. Although results for its long-term effects on vision are not yet available, ranibizumab is a promising alternative option to laser therapy for treating ROP.
- || Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Clinical, Journal: Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial. (Pubmed Central) - Feb 24, 2021
P4
Combination therapy with vPDT added to ranibizumab achieved superior BCVA gain, increased odds of complete polypoidal lesion regression, and fewer treatment episodes compared with ranibizumab monotherapy. ClinicalTrials.gov Identifier: NCT01846273.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial. (Pubmed Central) - Feb 24, 2021
P3
These automated spectral-domain OCT analyses may be used clinically to assess anatomical change during therapy. ClinicalTrials.gov Identifier: NCT01627249.
- || faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, P2 data, Journal: Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial. (Pubmed Central) - Feb 24, 2021
P2
Faricimab showed no new or unexpected safety signals. ClinicalTrials.gov Identifier: NCT02484690.
- || faricimab (RG7716) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, P2 data, Journal: Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial. (Pubmed Central) - Feb 24, 2021
P2
These results suggest a role for simultaneous neutralization of angiopoietin-2 and vascular endothelial growth factor A in providing sustained efficacy through extended durability, warranting further investigation. ClinicalTrials.gov Identifier: NCT03038880.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Outcomes of Eyes with nAMD Switched from Aflibercept to Ranibizumab Compared to Eyes Maintained on Aflibercept () - Feb 23, 2021 - Abstract #WEC2021WEC_32;
ClinicalTrials.gov Identifier: NCT03038880. CFT significantly increased in nAMD eyes that switched while remaining stable in a comparable group maintained on aflibercept.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Stopper Position and Volume Injected in Prefilled Syringes () - Feb 23, 2021 - Abstract #WEC2021WEC_24;
The stopper was positioned at specific distances behind the preprinted mark in ranibizumab and aflibercept PFS... Small changes in stopper position have significant impacts on volume and dose injected
- | Lucentis (ranibizumab) / Roche, Novartis, Rayoqta (abicipar pegol) / Molecular Partners, AbbVie
Journal: Abicipar pegol for neovascular age-related macular degeneration. (Pubmed Central) - Feb 23, 2021
Modifications to reduce pro-inflammatory components resulted in reduced inflammation (9.8%) in the MAPLE study. If this high inflammation rate can be further reduced, abicipar has the potential to decrease treatment burden for nAMD patients.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Short-Term Effect of Metabolic Control on Diabetic Macular Edema and Serum Cytokine Levels in Diabetic Patients with Unregulated Blood Glucose () - Feb 20, 2021 - Abstract #ESCRSWM2021ESCRS_WM_306;
It is possible to lower HbA1c levels by metabolic control, but metabolic control alone has limited value in the treatment of DME at 3 months period. The therapeutic effect of anti-VEGF treatment on DME supports the role of local cytokine milieu in pathophysiology rather than the systemic cytokine levels.
- ||| Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
P3 data, Journal: Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies. (Pubmed Central) - Feb 20, 2021
P3
In this post hoc analysis, fixed dosing with an anti-VEGF agent over 52 weeks eliminated disease activity (absence of both leakage and fluid) in most eyes. The effect of anti-VEGF treatment on leakage/fluid status favoured PC versus occult lesions.
- || Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Subthreshold laser therapy for macular oedema from branch retinal vein occlusion: focused review. (Pubmed Central) - Feb 20, 2021
Subthreshold laser therapy is safer and as effective as CLP for the treatment of ME associated with BRVO. SLT may be used in combination with anti-VEGF IVIs to enhance improvement in VA and ME resolution.
- |||||||||| sozinibercept (OPT-302) / Opthea
New P3 trial, Combination therapy: ShORe: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov) - Feb 16, 2021
P3, N=990, Not yet recruiting, Sponsor: Opthea Limited
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Review, Journal: Age-related macular degeneration: a review of current therapies and new treatments. (Pubmed Central) - Feb 16, 2021
Current studies are focused on new anti-vascular endothelial growth factor drugs, nucleoside reverse transcriptase inhibitors, antibody against sphingosine-1-phosphate, anti-platelet-derived growth factor, gene therapy, and RNA interference. The results of ongoing clinical studies may improve the therapy of age-related macular degeneration.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy. (Pubmed Central) - Feb 16, 2021
P4
Intravitreal injection alone or combined with single- or multiple-spot panretinal photocoagulation yielded similar outcomes with respect to mean change in best-corrected visual acuity, central subfield macular thickness, and fluorescein leakage from active neovascularization at up to one-year of follow-up. All subjects provided written informed consent to participate (NCT02005432 in clinicaltrials.gov).
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease. (Pubmed Central) - Feb 16, 2021
This study showed no functional and vascular improvement following 3 monthly ranibizumab injections. OCTA, non-invasive technique, could be useful during follow up of these patients and provide a better understand of pathogenesis of this disorder.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization. (Pubmed Central) - Feb 13, 2021
Both aflibercept and ranibizumab provided a significant improvement in visual acuity and retinal thickness in patients with myopic choroidal neovascularization. Comparable functional and architectural results were achieved by both treatment modalities.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration : Long-term retinal changes under anti-vascular endothelial growth factor treatment. (Pubmed Central) - Feb 13, 2021
Morphological findings may aid in the identification of prognostic markers in the progression of neovascular AMD. This could lead to a more targeted education of affected patients.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal, HEOR, Real-World Evidence: Real-World Treatment Patterns and Vision Outcomes with Ranibizumab for Diabetic Macular Edema. (Pubmed Central) - Feb 13, 2021
Intravitreal ranibizumab for diabetic macular edema was effective in a real-world clinical setting, with most eyes gaining or maintaining vision. Compared with randomized prospective clinical trials, patients received less frequent injections and achieved lower vision gains.
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Twelve-Month Treatment Outcomes of Macular Edema Following Central Retinal Vein Occlusion using Aflibercept or Ranibizumab in Routine Clinical Practice – Data from the Fight Retinal Blindness! Project () - Feb 11, 2021 - Abstract #Macula2021Macula_243;
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Effects of Ranibizumab on Changes in Drusen, Macular Volume, and Geographic Atrophy in Prophylactic Ranibizumab in Fellow Vulnerable High-Risk Eyes with Nonexudative AMD in Patient with Exudative AMD in One Eye (PREVENT), A Prospective Trial () - Feb 11, 2021 - Abstract #Macula2021Macula_189;
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Key Surgical Pearls of the Implant Insertion Procedure for the Port Delivery System With Ranibizumab (PDS) () - Feb 11, 2021 - Abstract #Macula2021Macula_164;
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Pharmacokinetic Profile of the Port Delivery System With Ranibizumab (PDS) in the Phase 3 Archway Trial (Live) - Feb 11, 2021 - Abstract #Macula2021Macula_154;
- Lucentis (ranibizumab) / Roche, Novartis
[VIRTUAL] Analysis of Central Subfield Thickness Fluctuations and Impact on Vision Outcomes in the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab (PDS) (Live) - Feb 11, 2021 - Abstract #Macula2021Macula_153;
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Review, Journal: The laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion: A protocol for systematic review and meta-analysis. (Pubmed Central) - Feb 11, 2021
Compared with randomized prospective clinical trials, patients received less frequent injections and achieved lower vision gains. Laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion has good effect, and the research has provided reliable evidence for the use of clinical treatment of the laser combined with intravitreal injection of ranibizumab for treatment of macular edema secondary to branch retinal vein occlusion.
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Journal: Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR). (Pubmed Central) - Feb 10, 2021
In eyes treated for wet AMD and studied for 2 years, 12.7% of eyes declined to a final VA of ≤ 35 letters. Visual acuity, worse-seeing eye treated, age and membrane size turned out as the baseline characteristics that had significantly influenced visual decline to ≤ 35 letters during the two-year follow-up.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Automated diagnosis and quantitative analysis of plus disease in retinopathy of prematurity based on deep convolutional neural networks. (Pubmed Central) - Feb 10, 2021
It provided a quantitative analysis of the dynamic features of the disease progression. This automated system can assist physicians by providing a classification decision with auxiliary quantitative evaluation of the typical pathological features of the disease.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Short-time effect of intravitreal injections on retinal vascular oxygenation and vessel diameter in patients with diabetic macular oedema or neovascular age-related macular degeneration. (Pubmed Central) - Feb 10, 2021
The observed changes can be interpreted as signs of increased metabolic demand during the physiological stress after an IVI. The abnormal arterial constriction and the abolished increase in AVD seen only in eyes with DME indicate an impairment of vascular autoregulation and oxygen distribution and a reduced neuroretinal metabolism in the diabetic retina with a significant impact on inner retinal oxygen consumption shortly after IVI.
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Eyes with Myopic Choroidal Neovascularization: 24-Month Follow-Up. (Pubmed Central) - Feb 9, 2021
The abnormal arterial constriction and the abolished increase in AVD seen only in eyes with DME indicate an impairment of vascular autoregulation and oxygen distribution and a reduced neuroretinal metabolism in the diabetic retina with a significant impact on inner retinal oxygen consumption shortly after IVI. Our study demonstrates that ranibizumab and aflibercept in a PRN regimen lead to a significant increase of BCVA and decrease in central foveal thickness in treatment-naive patients with myopic CNV after 24 months.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Sustained Elevation of Intraocular Pressure after Administration of Intravitreal Anti-vascular Endothelial Growth Factor Agents in Patients with and without Pseudoexfoliation Syndrome. (Pubmed Central) - Feb 9, 2021
IVB therapy may cause greater increases in IOP in patients with PXF syndrome. The co-accumulation of PXF material and bevacizumab particles on the trabecular meshwork should be further investigated.
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Review, Journal: Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options. (Pubmed Central) - Feb 9, 2021
Intravitreal therapy with anti-VEGFs or dexamethasone implant produces a significant improvement in BCVA at 12 months in patients with DME. Meta-regression identified the modifiable covariates that can be targeted in order to maximize functional results.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conventional fluorescein angiography. (Pubmed Central) - Feb 7, 2021
During ranibizumab therapy, external limiting membrane visibility showed a higher sensitivity (100%) compared with fuzzy borders and subretinal hyperreflective exudation (66.6%) while displaying an equal specificity of 100%...The study confirms that the new indicators of myopic choroidal neovascularization activity are more reliable than the presence or absence of retinal fluid. Optical coherence tomography angiography identified myopic choroidal neovascularization in most patients in the diagnostic phase and during treatment monitoring and could be considered as an alternative to fluorescein angiography in selected patients.
- || Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden. (Pubmed Central) - Feb 7, 2021
The treatment was changed again after the switch in 18% of the patients in the ranibizumab group and 19% in the aflibercept group and these subjects were excluded from the analyses. In patients with neovascular age-related macular degeneration, a switch from ranibizumab or aflibercept to bevacizumab seems possible without a significant decrease in visual acuity in most patients.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema. (Pubmed Central) - Feb 7, 2021
However, there were no significant changes of the other five factors/cytokines (placental growth factor, soluble intercellular adhesion molecule-1, interleukin-6, interleukin-12, and interleukin-13) at recurrence after intravitreal ranibizumab injection compared with baseline. These findings suggest that persistent inflammation may influence the recurrence of macular edema in branch retinal vein occlusion patients, and that adding steroid therapy might be an effective strategy for preventing recurrence.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity. (Pubmed Central) - Feb 7, 2021
Aggressive posterior retinopathy of prematurity is a serious, rapidly progressing form of retinopathy of prematurity that requires quick and proper management. This study indicates that primary treatment with ranibizumab and laser photocoagulation on recurrence provide favorable anatomical outcomes.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Experience with Intravitreal Ranibizumab as an Adjunct to Ablation Therapy in Eyes with Exudative Coats' Disease. (Pubmed Central) - Feb 7, 2021
External drainage should be preserved for when ablation therapy is not feasible. Future prospective trials with pre-defined outcomes are required.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: The association between intravitreal ranibizumab therapy and serum cytokine concentrations in patients with diabetic macular edema. (Pubmed Central) - Feb 5, 2021
In patients with DME, intravitreal ranibizumab therapy appears to influence the serum levels of a range of cytokines. After two injections, intravitreal ranibizumab therapy appears to be associated with a significant decrease in inflammatory mediators and a rise in VEGF and sVEGFR1.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Early Visual Functional Outcomes and Morphological Responses to Anti-Vascular Growth Factor Therapy in Diabetic Macular Oedema Using Optical Coherence Tomography Angiography. (Pubmed Central) - Feb 5, 2021
Scans were done at baseline and at 1 month following each of the 3 intravitreal injections of anti-VEGF (ranibizumab, Lucentis)...OCTA shows a reduction in VD and PD respectively suggestive of reduced macular perfusion in the short term. Simultaneous reduction in FAZ size can be due to reversal of manual displacement of the retinal capillaries resulting from resolution of intraretinal oedema.
- |||||||||| HLX04-O (bevacizumab biosimilar) - Fosun Pharma, Essex Bio / Technology
New P3 trial: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD (clinicaltrials.gov) - Feb 4, 2021
P3, N=388, Not yet recruiting, Sponsor: Shanghai Henlius Biotech
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: NOVEL CASE OF CLOSTRIDIUM PERFRINGENS ENDOPHTHALMITIS AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTION. (Pubmed Central) - Feb 4, 2021
However, it is an important pathogen to consider when there is rapid destruction of eye structures associated with endophthalmitis. Based on a root cause analysis of this case, our department has introduced patient information leaflets on hand hygiene to educate patients having intraocular injections.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Influence of Ranibizumab versus laser photocoagulation on radiation retinopathy (RadiRet) - a prospective randomized controlled trial. (Pubmed Central) - Feb 4, 2021
P2
This study showed a statistically significant improvement in visual acuity and clear superiority of ranibizumab compared to laser treatment up to 26 weeks, but this effect disappeared at week 52 after completion of intravitreal treatment. Ranibizumab and PRP are considered equivalent in terms of the non-appearance of proliferative radiation retinopathy during the study.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Emerging drugs for the treatment of diabetic retinopathy. (Pubmed Central) - Feb 4, 2021
Faricimab, active on Tie-2 receptors, is being evaluated in two phase 3 clinical trials. Further knowledge on the efficacy and safety of these drugs is necessary before their final approval for the treatment of diabetic retinopathy.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Host cell proteins induce inflammation and immunogenicity as adjuvants in an integrated analysis of in vivo and in vitro assay systems. (Pubmed Central) - Feb 2, 2021
These finding suggests that HCPs may induce inflammation and immunogenicity as an adjuvant. Furthermore, integrated analyses by an in vivo rabbit model and in vitro assay system using THP-1 cells would be useful to evaluate the immunological risk of HCPs.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Choroidal osteoma: the varied response of subretinal fluid to anti-VEGF agents. (Pubmed Central) - Feb 2, 2021
Furthermore, integrated analyses by an in vivo rabbit model and in vitro assay system using THP-1 cells would be useful to evaluate the immunological risk of HCPs. The present case shows a remarkable long-term response of the choroidal neovascular membrane and serous retinal detachment associated with choroidal osteoma to two injections of ranibizumab which is an anti-vascular endothelial growth factor (anti-VEGF) agent.
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis. (Pubmed Central) - Feb 2, 2021
P=N/A
In persistent DME unresponsive to bevacizumab, both anatomical and functional improvements were observed with ranibizumab whereas aflibercept only showed an anatomical improvement. Clinicaltrials.gov NCT04018833.